Hence, we examined the ability of several Food and Drug Administration (FDA)-approved chemotherapeutic agents to induce cell-surface shuttling of LUNX, which we proposed previously to be a promising tumor antigen in NSCLC [32, 42]. Here, BPIFA1 is linked to neoplasm.